KR20180116174A - Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of obesity containing the same - Google Patents

Abstract

Provided are a Lactobacillus plantarum Lb41 strain as a probiotic isolated from traditional fermented foods, and a use thereof. More specifically, provided is a use of the strain for anti-obesity. The Lactobacillus plantarum Lb41 strain isolated from the traditional fermented foods such as kimchi can be used as a probiotic, inhibits accumulation of fat in adipocytes, and shows significant body fat decreasing effects when administered to a high fat diet-induced mouse model having obesity. The Lactobacillus plantarum Lb41 strain of the present invention can be used as an active ingredient of a composition for preventing, treating, and ameliorating obesity.

Description

The novel Lactobacillus plantarum Lb41 strain and pharmaceutical composition for the prevention and treatment of obesity containing the same {Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of obesity containing the same}

The present invention is to provide a probiotic isolated from kimchi, Lactobacillus plantarum Lb41 (Lactobacillus plantarum Lb41) strain and its use, and more particularly, to provide an anti-obesity use of the strain.

Obesity is spreading very rapidly around the world. Currently, 1.7 billion people, which are 25% of the world's population, are overweight (BMI of 25 or more), and in Western regions, obesity patients with BMI of 30 or more are about 300 million. In addition, 1 in 5 children fall under pediatric obesity, and the number is rising rapidly, so only pediatric obesity is emerging as a serious social problem. In particular, in the case of obesity in children, the more fat, the more sex hormone secretion is stimulated, which can lead to growth disorders such as precocious puberty, and affects blood circulation and nutritional balance, which is the cause of growth inhibition. Obesity is a risk factor for major adult diseases, and is involved in the development of adult diseases such as high blood pressure, diabetes, arteriosclerosis, stroke, heart attack and various tumors (Wilson et al., 2005, Circulation 112: 3066-3072). , It is known that the risk of developing adult diseases due to obesity is 3 to 6 times higher than that of normal people.

Therefore, obesity is not just an appearance problem, but a serious problem directly related to health. To prevent obesity, it is important to increase the amount of exercise while maintaining the current amount of meal. In the case of obesity, the cause can be identified and the body can maintain a normal metabolism while maintaining an appropriate weight through an appropriate diet. It is desirable to do so.

On the other hand, kimchi, a traditional Korean fermented food made using various vegetables, is known to have various functions such as antioxidant, anti-aging, anti-obesity, anti-mutagenic, anti-inflammatory, antibacterial, anti-allergic, and immune-enhancing effects. These beneficial effects were derived from the nutrients in kimchi and the fermentation products of lactic acid bacteria. In kimchi, bacteria such as Lactobacillus , Leuconostoc , and Pediococcus are present and are involved in fermentation and aging of kimchi, so research using lactic acid bacteria isolated from kimchi and products using probiotics Are being released in various ways. Probiotics are beneficial microorganisms that enter the body in a living state and provide immunity and various functions to help health. Most of the probiotics known to date are lactic acid bacteria, of which Lactobacillus plantarum is a GRAS (Generally Recognized As Safe) strain recognized by the U.S. FDA and is a variety of fermented foods such as meat, vegetables, milk, and coffee for a long time. Has been used in In order to be recognized as probiotics, the strain must survive in the stomach and bile acids in the body to reach the small intestine, and must be able to grow by attaching to the intestinal epithelial cells. In addition, it should be non-toxic and non-pathogenic, and should exhibit useful effects such as antibacterial, anti-inflammatory, anti-cancer, antioxidant, anti-diabetic, and anti-obesity in the intestine. The functionality of these probiotics has been studied for a long time.

According to studies to date, it has been known that lactic acid bacteria isolated from fermented foods such as paste or kimchi can be used as probiotics, and can be applied as a pharmaceutical treatment through their various physiological functions. For example, in Korean Patent Registration No. 10-161653, a probiotic composition comprising a novel Lactococcus lactis KR-WW-2 strain isolated from flounder Sikhye is used to treat diseases caused by pathogens of farmed fish. It is disclosed that it can be used for treatment, and Korean Patent Laid-Open No. 10-2015-0106093 discloses that the Bacillus methylotrophicus C14 strain isolated from intestines can be used as a probiotic formulation and can be used as an antibacterial composition. I'm doing it. In addition to this, research for using various lactic acid bacteria as useful uses is ongoing.

Accordingly, the present inventors have tried to isolate lactic acid bacteria that can be used as probiotics from traditional fermented foods and find their use, and as a result, Lactobacillus plantarum Lb41 (Lactobacillus plantarum Lb41) strain isolated from kimchi can be used as a probiotic, and the above The present invention was completed by confirming that the strain can suppress the accumulation of fat in adipocytes and can exhibit a significant body fat reduction effect when administered to an obese mouse model induced by a high fat diet.

Accordingly, the present inventors can use the Lactobacillus plantarum Lb41 (Lactobacillus plantarum Lb41) strain isolated from traditional fermented foods as a probiotic, and when administered to an obese mouse model induced by a high fat diet, a significant anti-obesity effect is achieved. The present invention was completed by confirming that it can be represented.

Accordingly, an object of the present invention is to provide a novel Lactobacillus plantarum Lb41 (Lactobacillus plantarum Lb41) strain deposited with accession number KCCM 11896P.

In addition, another object of the present invention is to provide a probiotic formulation comprising the strain.

In addition, another object of the present invention is to provide a pharmaceutical use of the strain.

In order to achieve the above object, the present invention provides a Lactobacillus plantarum Lb41 (Lactobacillus plantarum Lb41) strain deposited with accession number KCCM 11896P.

In addition, the present invention provides a probiotic preparation containing the Lactobacillus plantarum Lb41 strain deposited under the accession number KCCM 11896P, a culture solution thereof, or a mixture thereof as an active ingredient.

In addition, the present invention provides a pharmaceutical composition for the prevention and treatment of obesity, containing Lactobacillus plantarum Lb41 strain deposited as an accession number KCCM 11896P, a culture solution thereof, or a mixture thereof as an active ingredient.

In addition, the present invention provides a health functional food for the prevention and improvement of obesity containing the Lactobacillus plantarum Lb41 strain deposited under the accession number KCCM 11896P, a culture medium thereof, or a mixture thereof as an active ingredient.

In a preferred embodiment of the present invention, the strain may have a 16S rRNA nucleotide sequence represented by SEQ ID NO: 1.

In another preferred embodiment of the present invention, the strain is characterized by having acid resistance, bile resistance, intestinal adhesion and antibiotic resistance.

In another preferred embodiment of the present invention, the Lactobacillus plantarum Lb41 strain may exhibit an effect of suppressing fat accumulation, suppressing appetite, and reducing body fat.

Lactobacillus plantarum Lb41 (Lactobacillus plantarum Lb41) strain isolated from kimchi can be used as a probiotic, which can inhibit the accumulation of fat in adipocytes, and is noted when administered to an obese mouse model induced by a high fat diet. Since it can exhibit an effective body fat reduction effect, the Lactobacillus plantarum Lb41 strain of the present invention can be used as an active ingredient of a composition for preventing, treating and improving obesity.

1 is a schematic diagram of a Lactobacillus plantarum Lb41 strain.
2 shows the effect of inhibiting fat accumulation in adipocytes according to Lactobacillus plantarum Lb41 treatment.
Figure 3 shows the effect of weight control according to the administration of Lactobacillus plantarum Lb41 in an animal model of obesity and metabolic disease induced by a high fat diet.
Figure 4 shows the appetite suppression effect according to the administration of Lactobacillus plantarum Lb41 in an animal model of obesity and metabolic disease induced by a high fat diet.
5 shows the effect of reducing body fat according to administration of Lactobacillus plantarum Lb41 in an animal model of obesity and metabolic disease induced by a high fat diet.

Hereinafter, the present invention will be described in detail.

The present invention provides a Lactobacillus plantarum Lb41 (Lactobacillus plantarum Lb41) strain deposited with accession number KCCM 11896P.

In addition, the present invention provides a probiotic formulation containing the Lactobacillus plantarum Lb41 strain, a culture solution thereof, or a mixture thereof as an active ingredient.

It is preferable that the "Lactobacillus plantarum Lb41 strain" of the present invention has a 16S rRNA nucleotide sequence represented by SEQ ID NO: 1.

The "Lactobacillus plantarum Lb41 strain" of the present invention preferably has acid resistance, bile resistance, intestinal adhesion and antibiotic resistance, but is not limited thereto.

Specifically, the acid resistance indicates that it can exhibit a survival rate of 99% or more for 3 to 5 hours even in a medium having a pH of 2 to 3, and the bile resistance may exhibit a survival rate of 80% or more for 24 hours in an environment similar to human bile. It is desirable to have. In addition, it shows the ability to bind the intestinal adhesion ability to a large intestine cell at a significant level. In order to use the Lactobacillus plantarum Lb41 strain of the present invention as a probiotic preparation, the effect may be reduced or enhanced through maintaining the viability of the strain even when administered orally in the body, so that it can survive in the environment in the digestive tract. Significant effects can be exhibited in those having acid resistance, bile resistance, and intestinal adhesion ability. In addition, the antibiotic resistance is preferably to have resistance to zetamicin, ciprofloxacin, kanamycin, and streptomycin, but is not limited thereto.

In a specific embodiment of the present invention, the present inventors isolated lactic acid bacteria that can be used as probiotics from traditional fermented foods, and isolated a new strain containing 16S rRNA composed of the nucleotide sequence shown in SEQ ID NO: 1, and homology thereof Through the analysis, it was confirmed that it was a novel strain of Lactobacillus plantarum Lb41 (FIG. 1), and it was deposited with the Korea Microbial Conservation Center (KCCM) on September 22, 2016 (Accession No. KCCM 11896P).

In addition, as a result of confirming the characteristics of Lactobacillus plantarum Lb41, it was confirmed that Lactobacillus plantarum Lb41 exhibits acid resistance, bile resistance, intestinal adhesion and resistance to some antibiotics. It was confirmed that it does not produce and does not show toxicity to normal cells (Tables 1 to 5), and through these characteristics, the Lactobacillus plantarum Lb41 strain of the present invention can be used in a probiotic preparation in the form of a live or apoptotic body. It was confirmed to be possible.

Therefore, the Lactobacillus plantarum Lb41 strain of the present invention is a novel strain that is safe for normal cells and has characteristics of acid resistance, bile resistance, and intestinal adhesion, so that the strain, its culture solution, or a mixture thereof is used as a probiotic formulation. It can be usefully used as an active ingredient of.

In addition, the present invention provides a pharmaceutical composition for the prevention and treatment of obesity, containing Lactobacillus plantarum Lb41 strain deposited as an accession number KCCM 11896P, a culture solution thereof, or a mixture thereof as an active ingredient.

It is preferable that the "Lactobacillus plantarum Lb41 strain" of the present invention has a 16S rRNA nucleotide sequence represented by SEQ ID NO: 1.

The "Lactobacillus plantarum Lb41 strain" of the present invention preferably has acid resistance, bile resistance, intestinal adhesion and antibiotic resistance, but is not limited thereto.

The "Lactobacillus plantarum Lb41 strain" of the present invention can exhibit a therapeutic effect on obesity through the effect of suppressing fat accumulation, suppressing appetite, and reducing body fat.

In another specific embodiment of the present invention, in order to confirm the anti-obesity effect of the Lactobacillus plantarum Lb41 strain, the present inventors constructed a mouse model in which metabolic syndrome was induced through a high fat diet. It was confirmed that when the Lactobacillus plantarum Lb41 strain was administered to the mouse model, the accumulation of fat in adipocytes was suppressed, and when administered to an obese mouse model induced by a high fat diet, a significant body fat reduction effect could be exhibited. It was (Figs. 2 to 5).

Therefore, when the Lactobacillus plantarum Lb41 strain of the present invention is administered as a viable cell, it is possible to inhibit the accumulation of fat in adipocytes, and exhibit a significant anti-obesity effect by exhibiting a body fat reduction effect. Bacillus plantarum Lb41 strain can be used as an active ingredient in a pharmaceutical composition for preventing and treating obesity.

The microbial preparation of the present invention may be prepared according to a conventional method for preparing a probiotic composition, and generally, may be in the form of a culture suspension or a dry powder. In addition, one or two or more pharmaceutically acceptable conventional carriers or one or two or more additives are selected in the effective amount of the Lactobacillus plantarum Lb41 strain, which is the main component, or a culture solution thereof, to obtain a composition of a conventional formulation. Can be manufactured.

The carrier can be used by selecting one or two or more of diluents, lubricants, binders, disintegrants, sweeteners, stabilizers, and preservatives, and one or two or more of flavors, vitamins, and antioxidants can be selected as additives. Can be used.

In the present invention, all pharmaceutically acceptable carriers and additives can be used, and specifically, as a diluent, lactose monohydrate, trehalose, cornstarch, soybean oil, Microcrystalline cellulose or mannitol (D-mannitorl) is preferred, magnesium stearate or talc is preferred as a lubricant, and polyvinyipyrrolidone (PVP: polyvinyipyrolidone) or hydroxypropyl as a binder. It is preferable to select from cellulose (HPC: hydroxypropylcellulose). In addition, the disintegrant is preferably selected from carboxymethylcellulose calcium (Ca-CMC), sodium starchglycolate, pollacrylin potassium, or cross-linked polyvinylpyrrolidone. And, the sweetener is selected from white sugar, fructose, sorbitol, or aspartame, and the stabilizer is carboxymethylcellulose sodium (Na-CMC), beta-cyclodextrin, and white wax. (white bee's wax) or xanthan gum, and the preservative is methyl p-hydroxy benzoate (methlparaben), propyl p-hydroxybenzoate (propylparaben), or potassium sorbate ( potassium sorbate).

In addition, the present invention provides a health functional food for the prevention and improvement of obesity containing the Lactobacillus plantarum Lb41 strain deposited under the accession number KCCM 11896P, a culture medium thereof, or a mixture thereof as an active ingredient.

It is preferable that the "Lactobacillus plantarum Lb41 strain" of the present invention has a 16S rRNA nucleotide sequence represented by SEQ ID NO: 1.

The "Lactobacillus plantarum Lb41 strain" of the present invention preferably has acid resistance, bile resistance, intestinal adhesion and antibiotic resistance, but is not limited thereto.

The "Lactobacillus plantarum Lb41 strain" of the present invention can exhibit a therapeutic effect on obesity through the effects of suppressing fat accumulation, suppressing appetite, and reducing body fat.

When the Lactobacillus plantarum Lb41 strain of the present invention is administered as a live cell, it can suppress the accumulation of fat in adipocytes, and when administered to an obese mouse model induced by a high fat diet, it can exhibit a significant body fat reduction effect. Therefore, the Lactobacillus plantarum Lb41 strain of the present invention can be used as an active ingredient in a health functional food for preventing and improving obesity.

The food composition according to the present invention can be prepared in various forms according to conventional methods known in the art. General foods include, but are not limited to, beverages (including alcoholic beverages), fruits and processed foods thereof (e.g., canned fruit, canned food, jam, marmalade, etc.), fish, meat and processed foods thereof (e.g. ham, sausage) Corn beef), breads and noodles (e.g. udon, soba, ramen, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, sweets, dairy products (e.g. butter, cheese, etc.), edible vegetable oil, margarine, Vegetable protein, retort food, frozen food, various seasonings (eg, miso, soy sauce, sauce, etc.) can be prepared by adding the Lb41 strain of the present invention to the Lactobacillus plantarum. In addition, the nutritional supplement may be prepared by adding the Lb41 strain of the present invention to capsules, tablets, pills, etc., but is not limited thereto. In addition, the health functional food is not limited thereto, but for example, the Lactobacillus plantarum Lb41 strain of the present invention itself is prepared in the form of tea, juice, and drinks, and liquefied, granulated, It can be encapsulated and powdered to be consumed. In addition, in order to use the Lactobacillus plantarum Lb41 strain of the present invention in the form of a food additive, it may be prepared and used in the form of a powder or a concentrate. In addition, it can be prepared in the form of a composition by mixing with the Lactobacillus plantarum Lb41 strain of the present invention and a known active ingredient known to have an effect of preventing and improving obesity.

When the Lactobacillus plantarum Lb41 strain of the present invention is used as a health drink, the health drink composition may contain various flavoring agents or natural carbohydrates as an additional component, such as a conventional drink. The natural carbohydrates described above include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin and cyclodextrin; It may be a sugar alcohol such as xylitol, sorbitol, and erythritol. Sweeteners include natural sweeteners such as taumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.

In addition, the Lactobacillus plantarum Lb41 strain of the present invention may be contained as an active ingredient in a food composition for preventing and improving obesity, and the amount is not particularly limited to an amount effective to achieve the action of preventing and improving obesity. , It is preferably 0.01 to 100% by weight based on the total weight of the total composition. The food composition of the present invention may be prepared by mixing Lactobacillus plantarum Lb41 strain with other active ingredients known to be effective in the composition for preventing and improving obesity.

In addition to the above, the health food of the present invention includes various nutrients, vitamins, electrolytes, flavoring agents, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, It may contain glycerin, alcohol, or a carbonating agent. In addition, the health food of the present invention may contain flesh for the manufacture of natural fruit juice, fruit juice beverage, or vegetable beverage. These ingredients may be used independently or in combination. Although the proportion of these additives is not very important, it is generally selected from 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrative purposes only, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not construed as being limited by these examples.

Isolation and acquisition of useful probiotic strains from kimchi

<1-1> Pure separation of kimchi-derived microorganisms

In order to carry out the examples of the present invention, microorganisms were purely isolated from kimchi.

Specifically, a kimchi sample was prepared by diluting kimchi broth such as cabbage kimchi, yeolmu kimchi, and kkakdugi in distilled water in ^{a ratio of 10 -1} to 10 ^-7. Then, the kimchi sample was plated on MRS agar medium, LBS agar medium, or PES agar medium, which is a lactic acid bacteria selection medium. The smeared medium was cultured at 37° C. to obtain colonies, and the morphology was observed. Strokes were streaked several times on a new medium, and microorganisms were purely separated.

<1-2> Identification of isolated lactic acid bacteria

In order to confirm what strain the microorganisms purely isolated through the lactic acid bacteria selection medium were, the isolated microorganisms were identified.

Specifically, genomic DNA was extracted from the strain isolated in Example <1-1>, and the nucleotide sequence was analyzed (Bionics, commissioned by Korea) to obtain the gene nucleotide sequence of 16S rRNA. The nucleotide sequence of the 16S rRNA was analyzed for homology with other standard strains registered in the database using the BLAST program, and was identified as a strain exhibiting 98% or more homology. In addition, homology was analyzed and a schematic was constructed using Cluster X and Mega 7 programs.

The result, called the lactic acid bacteria is Lactobacillus Planta room (Lactobacillus plantarum) with Lactobacillus Planta room Lb41 (Lactobacillus plantarum Lb41) showed a homology with the reported strain separated from Kimchi, as also shown in Figure 1, It was deposited with the Korea Microbial Conservation Center (KCCM) on September 22, 2016 (Accession No. KCCM 11896P).

Characterization of Lactobacillus plantarum Lb41 strain

<2-1> Confirmation of acid resistance and bile resistance of Lactobacillus Platarum Lb41

In order to confirm the characteristics of Lactobacillus plantarum Lb41 isolated from kimchi, acid resistance and bile resistance were confirmed.

Specifically, first, Lactobacillus plantarum Lb41 strain was inoculated into an artificial gastric juice medium (pH 2.5) of a 0.3% pepsin aqueous solution in order to confirm acid resistance, followed by stationary culture for 3 hours. After cultivation, the bacteria were obtained, plated on a plate medium, incubated at 37°C for 48 hours, and then the number of colonies generated was counted to measure the number of viable bacteria to confirm the relative number of viable bacteria to the number of viable bacteria in the solvent control group.

In addition, in order to confirm bile resistance, Lactobacillus plantarum Lb41 strain was inoculated into a medium of 0.3% oxgall and cultured for 24 hours. After cultivation, bacteria were obtained and the relative number of viable bacteria was confirmed by the same method. For comparison of acid resistance and bile resistance, commercial strains, L. plantarum KCTC 10782BP strain and L. acidophilus KCTC 11906BP strain, were cultured under the same conditions as above to confirm stability.

As a result, as shown in the following [Table 1], the Lactobacillus plantarum Lb41 strain was confirmed to exhibit excellent acid resistance by decreasing the number of bacteria by 0.06 Log CUF/ml from the initial number of bacteria when incubated for 3 hours in an artificial gastric juice medium. (Table 1). In addition, it was confirmed that bile resistance decreased by 1.36 Log CFU/ml when compared to the initial bacterial count when cultured for 24 hours, indicating bile resistance, and these acid resistance and bile resistance characteristics were more significant than the control strains of commercial strains. It was confirmed that it showed a high level of stability.

Confirmation of acid resistance and bile resistance of Lactobacillus plantarum Lb41 strain Treatment group Number of bacteria (Log CFU/mL) L. plantarum
Lb41 L. acidophilus
KCTC 11906BP L. plantarum
KCTC 10782BP Initial bacterial count 8.54±0.05 9.02±0.02 8.62±0.01 Artificial gastric juice (pH 2.5, 0.3% pepsin, 3 h) 8.48±0.01 7.99±0.01 8.47±0.03 Artificial bile (0.3% oxgall, 24 h) 7.18±0.07 6.55±0.07 5.91±0.13

<2-2> Confirmation of the enzyme production ability of Lactobacillus plantarum Lb41

To confirm the characteristics of Lactobacillus plantarum Lb41 isolated from kimchi, we investigated whether the Lactobacillus plantarum Lb41 strain can produce various enzymes such as β-glucuronidase, which causes carcinogenesis. Whether it was confirmed.

Specifically, the Lactobacillus plantarum Lb41 strain was cultured until the logarithmic growth phase, and then centrifuged at 10,000×g for 10 minutes to remove the supernatant medium. After removing the medium, the obtained strain was washed with a PBS buffer solution, and then the substrate of the API ZYM kit was mixed with the washed strain and incubated for 4 hours. Then, solutions A and B of the kit were added, respectively, and reacted for 5 minutes at a high light source, and then, according to the degree of color development, whether or not enzyme was produced was confirmed.

As a result, as shown in Table 2 below, Lactobacillus plantarum Lb41 is β-glucuronidase, N-acetyl-β-glucosaminidase, which causes carcinogenesis. ), it was confirmed that it is safe for the human body (Table 2).

Confirmation of enzyme production ability of Lactobacillus plantarum Lb41 strain Enzyme Enzyme activity (nmole) Lactobacillus plantarum Lb41 Control 0 Alkaline phosphatase 0 Esterase 0 Esterase lipase 0 Lipase 0 Leucine arylamidase 2 Valine arylamidase One Cystine arylamidase 0 Trypsin 0 α-Chymotrypsin 0 Acid phosphatase One Naphthol-AS-BI-phosphohydrolase One α-Galactosidase 0 β-Galactosidase 5 β-Glucuronidase 0 α-Glucosidase 0 β-Glucosidase 5 N-Acetyl-β-glucosaminidase 0 α-Mannosidase 0 α-Fucosidase 0

(In the above table, 0 represents the production of 0 to 5 nmol of enzyme; 1 represents the production of 5 to 10 nmol of enzyme; 2 represents the production of 10 to 20 nmol of enzyme; 3 represents 20 to Represents to produce 30 nmol of enzyme; 4 represents to produce 30 to 40 nmol of enzyme; and 5 represents to produce 40 nmol or more of enzyme.)

<2-3> Confirmation of intestinal adhesion ability of Lactobacillus plantarum Lb41

In order to confirm the characteristics of Lactobacillus plantarum Lb41 isolated from kimchi, the intestinal adhesion ability of the Lactobacillus plantarum Lb41 strain was confirmed.

Specifically, colon cancer cells HT-29 cells were inoculated into a 96-well plate and then cultured for 24 hours ^{to prepare MRC-5 cells at a concentration of 1×10 5} cells/ml. Then, the Lactobacillus plantarum Lb41 strain was cultured until the logarithmic growth phase, and then centrifuged at 10,000×g for 10 minutes to remove the supernatant medium. After removing the medium, the obtained strain was washed with a PBS buffer solution, and the obtained Lactobacillus plantarum Lb41 strain was inoculated on the prepared HT-29 culture plate at a concentration of 8.68±0.16 log CFU/well and incubated for 2 hours. I did. After incubation, washing was repeated three times with PBS buffer solution, and then treated for 10 minutes by adding 1 ml of Triton-X100, centrifuged, a supernatant was obtained, plated on lactobacilli MRS agar medium, and incubated for 48 hours at 37°C. The number of colonies generated was checked, and the number of bacteria attached to the colon cancer cell line and the number of bacteria remaining in the medium (the number of colonies generated) were compared to confirm the intestinal adhesion ability.

As a result, as shown in the following [Table 3], it was confirmed that the Lactobacillus plantarum Lb41 strain had a very good intestinal adhesion ability by attaching 7.5% of cells, which was significantly higher than the commercial control strain. It was confirmed that it represents.

Confirmation of intestinal adhesion ability of Lactobacillus plantarum Lb41 Treatment group Number of bacteria (Log CFU/mL) L. plantarum Lb41
Initial bacterial count (0 h) 8.68±0.16 Number of bacteria attached (2 h) 7.57±0.06 L. acidophilus
KCTC 11906BP Initial bacterial count (0 h) 7.94±0.10 Number of bacteria attached (2 h) 6.55±0.08 L. plantarum
KCTC 10782BP Initial bacterial count (0 h) 8.65±0.02 Number of bacteria attached (2 h) 7.58±0.08

<2-5> Confirmation of antibiotic resistance of Lactobacillus plantarum Lb41

In order to confirm the characteristics of Lactobacillus plantarum Lb41 isolated from kimchi, it was confirmed whether the Lactobacillus plantarum Lb41 strain exhibits resistance to antibiotics used in the CLSI (Clinical and Laboratory Standards Institute, 2012) criteria. .

Specifically, the Lactobacillus plantarum Lb41 strain was cultured until the logarithmic growth phase, and then centrifuged at 10,000×g for 10 minutes to remove the supernatant medium. After removing the medium, the obtained strain was washed with a PBS buffer solution, ^{diluted to a concentration of 10 5} CFU/ml, spread on lactobacilli MRS agar medium, and cultured until the surface of the medium was saturated with Lactobacilli plantarum Lb41. Then, the sterilized paper disc was placed in 0.2 mg/ml ampicillin, 0.6 mg/ml tetracycline, 0.2 mg/ml zetamicin, 0.1 mg/ml ciprofloxacin, 0.6 mg/ml Kanamycin, 0.6 mg/ml Chloramphenicol, 0.2 mg/ml Streptomycin or 0.6 mg/ml Doxycycline, respectively, and the cultured Lactobacillus plaque Lantarum Lb41 strain was placed on the medium surface. And the degree of antibiotic resistance was determined according to the size of the growth inhibition zone (inhibition zone) produced by incubation at 37°C for 24 hours.

As a result, as shown in the following [Table 4], Lactobacillus plantarum Lb41 is sensitive to ampicillin, tetracycline, chloramphenicol and doxocycline, and shows resistance to zetamicin, ciprofloxacin, kanamycin, and streptomycin. Confirmed (Table 4).

Confirmation of antibiotic resistance of Lactobacillus plantarum Lb41 Antibiotics Lactobacillus plantarum Lb41 Antibiotics Lactobacillus plantarum Lb41 Ampicillin S Tetracycline S Gentamycin R Ciprofloxacin R Kanamycin R Chloramphenicol S Streptomycin R Doxycycline S

(In the above table, R represents antibiotic resistance and S represents antibiotic sensitive.)

Preparation of live cells and dead cells of Lactobacillus plantarum Lb41

To confirm the pharmaceutical efficacy of Lactobacillus plantarum Lb41 of the present invention in vitro and in vivo , live cells and dead cells of Lactobacillus plantarum Lb41 were prepared.

Specifically, the Lactobacilli plantarum Lb41 isolated and identified in the <Example 1> was inoculated into a lactobacilli MRS liquid medium, incubated at 37°C for 18 hours, and then centrifuged at 5,000×g for 10 minutes to precipitate the cells. And separated into the supernatant of the culture solution. Then, the separated precipitate was lyophilized to obtain it as a live cell, and the live cell was heat-treated at 121° C. for 5 minutes to prepare and obtain a dead cell.

Lactobacillus Planta Room Of Lb41 Anti-obesity Check the effect

<4-1> Confirmation of Lactobacillus Plantarum Lb41's ability to inhibit fat accumulation

To determine whether the Lactobacillus plantarum Lb41 of the present invention can exhibit an anti-obesity effect at an in vitro level, the effect of inhibiting fat accumulation in adipocytes was confirmed.

Specifically, 3T3-L1 cells, which are adipocyte progenitor cell lines, were inoculated in DMEM medium, and then cultured in a 5% CO ₂ incubator at 37° C. until the saturation of the plate reached 100%. When the plate was grown to fill the cells, 10% FBS/DMEM differentiation medium containing 5 μg/ml insulin, 115 μg/ml IBMX and 10 μM dexamethasone was exchanged as a cell medium, and further cultured for 2 days. . At this time, 100 μg/ml of Lactobacillus plantarum Lb41 dead cells prepared in Example 3 was added to the differentiation medium. After 2 days of culture, the Lactobacillus plantarum Lb41 dead cells were exchanged with 10% FBS/DMEM medium containing 100 μg/ml and 5 μg/ml insulin and cultured for 4 to 6 days to differentiate from adipocytes. Adipocytes were obtained. The obtained adipocytes were fixed by adding a 10% formalin aqueous solution, and treated with an Oil Red O solution to react for about 15 minutes to 2 hours to stain the fat accumulated in the cells. After completion of the dyeing, after observation under a microscope, the Oil Red O solution was dissolved again with isopropyl alcohol, and the absorbance was measured at a wavelength of 518 nm. As a control, a non-differentiated undifferentiated cell control (ND, non-differentiated) and a differentiated cell control (D, differentiated) differentiated in a medium to which dead cells were not added were used. The degree of increase in the absorbance level was calculated using the following [Equation 1].

[Equation 1]

As a result, it was confirmed that the level of fat accumulation was reduced in the Lactobacillus plantarum Lb41-treated experimental group of the present invention when compared with the differentiated cell control group (D) as shown in FIG. 2, and stained red even through microscopic observation. It was confirmed that the number and size of fat cells significantly decreased (FIG. 2).

<4-2> Preparation of an obesity-inducing animal model by a high fat diet

To determine whether Lactobacillus plantarum Lb41 can exhibit a significant anti-obesity effect in a metabolic disease-induced animal model, an obesity-inducing mouse model, which is a subject experimental animal, was constructed.

Specifically, the Lactobacillus plantarum Lb41 live cells prepared in Example 3 ^{were suspended in distilled water at a concentration of 2.5×10 9} CFU/ml to prepare a strain sample. Then, 0.2 ml of the prepared strain sample was orally administered daily to 6-week-old C57/BL6 mice while freely feeding high-fat feed, and 5×10 ⁸ CFU was administered daily. The high fat feed was used in the form of a pellet containing 21.0% protein, 24.6% carbohydrates and 54.4% fat based on the caloric value (㎉) of the total feed. Mice after administration of strain samples and feeding high-fat feed in the same environment for a total of 5 weeks were used as Lactobacillus plantarum Lb41-administered obesity induction experimental group (Lb41). In order to compare the results of the Lb41 experimental group, the group that was reared in the same environment while administering live cells and self-supplied with normal feed was used as a normal control, and a high-fat feed was fed without administration of live cells while rearing in the same environment. The self-paying group was used as the high fat diet induction group (HFD). Lb41 experimental group, normal control group and HFD induction group checked each body weight to determine whether diabetes and metabolic diseases were induced by a high fat diet, and at the same time, whether the effect of weight loss by Lactobacillus plantarum Lb41 appeared. I did.

As a result, as shown in FIG. 3, it was confirmed that the weight gain of the HFD-inducing group was significantly higher from 1 week after breeding compared to the normal control group, compared to the weight gain of the HFD group, in the oral administration group of Lb41 probiotics (Lb41). It was confirmed that the level of weight gain was significantly reduced (FIG. 3). In addition, it was confirmed that this decrease in the level of weight gain was due to the appetite suppressing effect in the oral administration group of the Lb41 probiotic (FIG. 4). In the experimental group in which Lb41 probiotic was administered while ingesting a high fat diet, it was confirmed that the dietary intake decreased by 12.3% compared to the HFD control group.

<4-3> Analysis of the effect of Lactobacillus plantarum Lb41 on reducing body fat

To determine whether Lactobacillus plantarum Lb41 can exhibit a significant anti-obesity effect in a metabolic disease-induced animal model, the effect of reducing body fat in an animal model inducing metabolic disease was confirmed.

Specifically, after analyzing the weight control efficacy in the Lb41 probiotic administration group (Lb41) and the control group that induced metabolic disease for 5 weeks by the method of Example <4-2>, the epididymal fat, which is a representative visceral fat, was separated and the weight was measured. It was measured. Then, compared with the weight of epididymis fat before administration of the high fat diet, the level of increase in fat weight due to induction of the high fat diet for 5 weeks was calculated relatively.

As a result, as shown in FIG. 5, when compared to the control group fed with a normal diet, the control group (HFD) inducing a high-fat diet increased the weight of epididymis fat to about twice the level, but in the experimental group (Lb41), the HFD group Compared to, it was confirmed that the level of increase in the weight of epididymis fat decreased significantly (FIG. 5).

Korea Microorganism Conservation Center (overseas) KCCM11896P 20160922

<110> Konkuk University Industrial Cooperation Corp KOREA FOOD RESEARCH INSTITUTE <120> Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of obesity containing the same <130> 1061536 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 1404 <212> RNA <213> Lactobacillus plantarum <400> 1 aaggttaccc caccgacttt gggtgttaca aactctcatg gtgtgacggg cggtgtgtac 60 aaggcccggg aacgtattca ccgcggcatg ctgatccgcg attactagcg attccgactt 120 catgtaggcg agttgcagcc tacaatccga actgagaatg gctttaagag attagcttac 180 tctcgcgagt tcgcaactcg ttgtaccatc cattgtagca cgtgtgtagc ccaggtcata 240 aggggcatga tgatttgacg tcatccccac cttcctccgg tttgtcaccg gcagtctcac 300 cagagtgccc aacttaatgc tggcaactga taataagggt tgcgctcgtt gcgggactta 360 acccaacatc tcacgacacg agctgacgac aaccatgcac cacctgtatc catgtccccg 420 aagggaacgt ctaatctctt agatttgcat agtatgtcaa gacctggtaa ggttcttcgc 480 gtagcttcga attaaaccac atgctccacc gcttgtgcgg gcccccgtca attcctttga 540 gtttcagcct tgcggccgta ctccccaggc ggaatgctta atgcgttagc tgcagcactg 600 aagggcggaa accctccaac acttagcatt catcgtttac ggtatggact accagggtat 660 ctaatcctgt ttgctaccca tactttcgag cctcagcgtc agttacagac cagacagccg 720 ccttcgccac tggtgttctt ccatatatct acgcatttca ccgctacaca tggagttcca 780 ctgtcctctt ctgcactcaa gtttcccagt ttccgatgca cttcttcggt tgagccgaag 840 gctttcacat cagacttaaa aaaccgcctg cgctcgcttt acgcccaata aatccggaca 900 acgcttgcca cctacgtatt accgcggctg ctggcacgta gttagccgtg gctttctggt 960 taaataccgt caatacctga acagttactc tcagatatgt tcttctttaa caacagagtt 1020 ttacgagccg aaacccttct tcactcacgc ggcgttgctc catcagactt tcgtccattg 1080 tggaagattc cctactgctg cctcccgtag gagtttgggc cgtgtctcag tcccaatgtg 1140 gccgattacc ctctcaggtc ggctacgtat cattgccatg gtgagccgtt accccaccat 1200 ctagctaata cgccgcggga ccatccaaaa gtgatagccg aagccatctt tcaagctcgg 1260 accatgcggt ccaagttgtt atgcggtatt agcatctgtt tccaggtgtt atcccccgct 1320 tctgggcagg tttcccacgt gttactcacc agttcgccac tcactcaaat gtaaatcatg 1380 atgcaagcac caatcaatac caga 1404

Claims (6)

Lactobacillus plantarum Lb41 deposited with Accession No. KCCM 11896P, a culture thereof or a mixture thereof as an active ingredient.
The pharmaceutical composition for preventing and treating obesity according to claim 1, wherein the strain has the 16S rRNA base sequence set forth in SEQ ID NO: 1.
The pharmaceutical composition for preventing and treating obesity according to claim 1, wherein the strain has acid resistance, biliary properties, intestinal adhesiveness and antibiotic resistance.
The pharmaceutical composition for preventing and treating obesity according to claim 1, wherein the Lactobacillus plantarum Lb41 strain exhibits a fat accumulation inhibitory effect, an appetite suppressing effect and a body fat reducing effect.
Lactobacillus plantarum Lb41 deposited with the deposit number KCCM 11896P, a culture solution thereof or a mixture thereof as an active ingredient.
The health functional food according to claim 5, wherein the Lactobacillus plantarum Lb41 strain is characterized by a fat accumulation inhibitory effect and a body fat reducing effect.

Images